In MS, induction of endogenous IFN production in progressive-MS patients showed that some patients with improving symptoms had high levels of serum IFN-γ, while worsening clinical symptoms was related to low serum IFN-γ levels [37]. The gene discussed is IFNA1; the disease is myeloid sarcoma.